Comment: Kidney surgery may be unneeded in many intermediate-risk patients

Bookmark and Share
Published: 3 Jun 2018
Views: 1296
Dr Sumanta Pal & Prof Richard Schilsky

Dr Sumanta Pal and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a trial in which 450 patients with metastatic renal cell carcinoma (mRCC) were randomised to receive either TKI inhibitor sunitinib alone or sunitinib and nephrectomy.

For more on these results, watch Dr Mejean present the findings, watch Dr Mejeans interview with ecancer here, and read our news coverage here.